Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study Of Intravenous Metronidazole For Intrabdominal Infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 16 years of age or older.~* Diagnosed with intra-abdominal infections or pelvic inflammatory diseases.~* Can be obtained a specimen for bacteriological efficacy assessment.~Exclusion Criteria:~* Known or suspected hypersensitivity, intolerance or contraindication to Metronidazole, Ceftriaxone sodium, or other cephem antibiotics.~* Severe renal dysfunction (creatinine clearance \< 30 mL/min.) Reference: Cockcroft-Gault calculation formula.~* Hepatic dysfunction (AST, ALT, total bilirubin \> 3 times upper limit of normal range values).~* Severe underlying disease; patients in which drug clinical evaluation is difficult because of confounding diseases.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Metronidazole (Type: EXPERIMENTAL): Metronidazole will be administered at a dose of 500 mg TID (or QID for refractory or severe infection) in combination with ceftriaxone sodium

Based on this trial design, predict the completion outcome and termination type (if applicable).